Karyopharm Therapeutics
KPTI
114 hedge funds and large institutions have $58.6M invested in Karyopharm Therapeutics in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 24 increasing their positions, 33 reducing their positions, and 26 closing their positions.
1,238% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $89K
4% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 26
1% more funds holding
Funds holding: 113 → 114 (+1)
0.72% less ownership
Funds ownership: 4.33% → 3.61% (-0.72%)
27% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 33
48% less capital invested
Capital invested by funds: $113M → $58.6M (-$54.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.57M |
| 2 |
Jane Street
New York
|
+$1.52M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.32M |
| 4 |
Millennium Management
New York
|
+$1M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$905K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$6.93M |
| 2 |
BlackRock
New York
|
-$5.83M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.02M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.33M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$755K |
KPTI Hedge Fund Activity: Q2 2024 in Review
114 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2024, worth a combined $58.6M — down 48% from $113M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new KPTI positions and 26 closed out — a net gain of 1 holder — while 24 added to existing stakes and 33 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $1.57M. The largest seller was Avidity Partners Management, cutting an estimated $6.93M.
- 114 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2024, up from 113 in Q1 2024.
- Funds reported $58.6M of Karyopharm Therapeutics stock for Q2 2024, down 48% quarter-over-quarter.
- 27 funds opened new Karyopharm Therapeutics positions in Q2 2024 and 26 closed out, a net change of +1 holder.
- The largest Karyopharm Therapeutics buyer in Q2 2024 was Opaleye Management, an estimated $1.57M added.
- The largest Karyopharm Therapeutics seller in Q2 2024 was Avidity Partners Management, an estimated $6.93M sold.
Based on aggregated 13F filings for Q2 2024.